Saturday, October 25, 2014 Last update: 2:03 PM - Covering Large & Obscure Tech Companies Since 1996

Hunter J. Shkolnik and Claimants' Negotiating Counsel Achieve Settlement in Pradaxa Litigation

Companies mentioned in this article: Napoli Bern Ripka Shkolnik LLP

NEW YORK, May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and its affiliated companies, and the Plaintiffs' Negotiating Counsel Committee appointed by a federal judge to seek resolution of all lawsuits related the use of Pradaxa in In Re Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385, and litigation pending in the State of Delaware being litigated by Napoli Bern Ripka Shkolnik today negotiated a settlement program to resolve the claims of approximately 4,000 Pradaxa users who claimed to have been injured by the drug.

Pradaxa, an anticoagulant prescribed to lower stroke risk among those suffering from a heart condition known as atrial fibrillation, was approved for use in the United States by the FDA in October, 2010. Approximately 1,600 individuals have filed lawsuits in state and federal courts in the United States, alleging they suffered bleeding events caused by Pradaxa. In August 2012, the federal court claims were consolidated in a multi-district litigation before Hon. David. R. Herndon. Likewise, consolidated state proceedings exist in Connecticut, California, Delaware and Missouri. Lawyers across these different jurisdictions worked cooperatively together to litigate the case.

The company will pay $650 million to fund the payments called for in today's settlement.

Hunter J. Shkolnik, specially appointed by Chief Judge Herndon as a designated negotiating counsel for all the Plaintiffs, said, "We are pleased that today's settlement will bring justice and financial assistance to those hurt while taking Pradaxa. We are proud of the settlement we have achieved, congratulate the company on doing the right thing, and look forward to distributing these funds to our clients as expeditiously as possible."

The trial lawyers of Napoli Bern Ripka Shkolnik LLP have led the Delaware State Coordinated Pradaxa litigation from start to finish, and are leading the way to resolution for all injured users of Pradaxa.

Napoli Bern Ripka Shkolnik LLP is nationally known for its work in a diverse range of practices areas, including defective prescription drugs & medical devices. Our attorneys hold numerous leadership positions (lead or liaison counsel, members of litigation steering committees) in numerous multi-district litigations for pharmaceutical cases and we represent thousands of victims in such cases.

Since 2000, our firm has recovered nearly $3 billion in verdicts & settlements for our clients.

Napoli Bern Ripka Shkolnik LLP
350 5th Avenue, Suite 7413,
New York, NY 10118.
Phone: (212) 267-3700.

SOURCE Napoli Bern Ripka Shkolnik LLP